BOLD Key Statistics, Chart & Performance
The current stock price of BOLD is 1.17 USD. In the past month the price decreased by -2.5%. In the past year, price decreased by -52.44%.
BOLD Latest News, Press Relases and Analysis
BOLD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About BOLD
Company Profile
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company is headquartered in San Diego, California and currently employs 64 full-time employees. The company went IPO on 2024-03-28. Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.
Company Info
BOUNDLESS BIO INC
10955 Alexandria Way, Suite 100
San Diego CALIFORNIA 94108 US
CEO: Matthew R. Patterson
Employees: 64
Phone: 18587669912
BOUNDLESS BIO INC / BOLD FAQ
What does BOLD do?
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company is headquartered in San Diego, California and currently employs 64 full-time employees. The company went IPO on 2024-03-28. Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.
What is the current price of BOLD stock?
The current stock price of BOLD is 1.17 USD. The price increased by 1.74% in the last trading session.
Does BOLD stock pay dividends?
BOLD does not pay a dividend.
What is the ChartMill technical and fundamental rating of BOLD stock?
BOLD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is BOUNDLESS BIO INC (BOLD) stock traded?
BOLD stock is listed on the Nasdaq exchange.
How is the market expecting BOLD stock to perform?
7 analysts have analysed BOLD and the average price target is 3.06 USD. This implies a price increase of 161.54% is expected in the next year compared to the current price of 1.17.
What is BOUNDLESS BIO INC worth?
BOUNDLESS BIO INC (BOLD) has a market capitalization of 26.20M USD. This makes BOLD a Nano Cap stock.
BOLD Technical Analysis
BOLD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BOLD. No worries on liquidiy or solvency for BOLD as it has an excellent financial health rating, but there are worries on the profitability.
BOLD Financial Highlights
Over the last trailing twelve months BOLD reported a non-GAAP Earnings per Share(EPS) of -2.77. The EPS decreased by -484.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.6% | ||
| ROE | -56.06% | ||
| Debt/Equity | 0 |
BOLD Forecast & Estimates
7 analysts have analysed BOLD and the average price target is 3.06 USD. This implies a price increase of 161.54% is expected in the next year compared to the current price of 1.17.